Product Description
Efavirenz is used along with other medications to treat human immunodeficiency virus (HIV) infection. Efavirenz is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by decreasing the amount of HIV in the blood. Although efavirenz does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. (Sourced from: https://medlineplus.gov/druginfo/meds/a699004.html)
Mechanisms of Action: NNRT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: HIV Infections
Known Adverse Events: Dizziness
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Burkina Faso, Cameroon, China, Czech Republic, France, Ivory Coast, Netherlands, New Zealand, Poland, United Kingdom, United States
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: HIV Infections
Phase 1: Breast Cancer|Fallopian Tube Cancer|Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Lymphoma, B-Cell|Malaria|Oncology Solid Tumor Unspecified|Oncology Unspecified|Ovarian Cancer|Peritoneal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MODERATO | P3 |
Active, not recruiting |
HIV Infections |
2025-02-05 |
|
| CTR20222508 | P1 |
Completed |
Lymphoma, B-Cell |
2023-01-27 |
|
| SHR1459-I-110 | P1 |
Completed |
Healthy Volunteers|Oncology Unspecified |
2022-12-02 |
39% |
| SHR1459-I-110 | P1 |
Completed |
Healthy Volunteers|Oncology Unspecified |
2022-12-02 |
39% |
| CKAF156A2107 | P1 |
Completed |
Malaria |
2022-11-22 |
21% |
| CKAF156A2107 | P1 |
Completed |
Malaria |
2022-11-22 |
21% |